Nexavar® Receives Positive Opinion From European Committee For Medicinal Products For Human Use For Treatment Of Liver Cancer
Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion, recommending to grant marketing authorization for Nexavar® (sorafenib) tablets for the treatment of patients with hepatocellular carcinoma (HCC), or liver cancer. [click link for full article]
More: continued here
Filed under: Cancer on September 25th, 2007